RA Capital Management, LP (RA Capital), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies, today ...

AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $175.67 which represents a decrease of $-0.90 or -0.51% from the prior close of $176.57. The stock opened at $175.53 and touched a low of $173.

There’s no question which company rules the semiconductor space—but a fight is ramping up over who comes next.

GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment ...

The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...

We recently compiled a list of the 11 Best Cosmetic Surgery and Aesthetics Stocks to Invest in Now. In this article, we are ...

The stock's fall snapped a two-day winning streak.

Astrocytes are star-shaped glial cells in the central nervous system that support neuronal function, maintain the blood-brain ...

In a report released today, Steve Scala from TD Cowen maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $176.19 which represents a slight increase of $0.02 or 0.01% from the prior close of $176.17. The stock opened at $176 and touched a low ...